Home
SCLXW
SCLXW News

Latest Scilex Holding Company (SCLXW) News on December 18, 2024

Argus Research

7 hours ago

Daily – Vickers Top Insider Picks for 12/18/2024

Argus Research

a day ago

Daily – Vickers Top Insider Picks for 12/17/2024

Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

GlobeNewswire

2 days ago

Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

Argus Research

2 days ago

Daily – Vickers Top Insider Picks for 12/16/2024

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

GlobeNewswire

5 days ago

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

Argus Research

5 days ago

Daily – Vickers Top Insider Picks for 12/13/2024

Scilex Holding Company Announces $17 Million Registered Direct Offering

GlobeNewswire

6 days ago

Scilex Holding Company Announces $17 Million Registered Direct Offering

Argus Research

6 days ago

Daily – Vickers Top Insider Picks for 12/12/2024

MT Newswires

7 days ago

Scilex Holding Venture Initiates Trial Enrollment for Alzheimer's Treatment

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

GlobeNewswire

7 days ago

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor

GlobeNewswire

7 days ago

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor

Argus Research

7 days ago

Daily – Vickers Top Insider Picks for 12/11/2024

Zacks Small Cap Research

8 days ago

SCLX Gets Exclusive Rights to Important Drug

NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes Collaboration for Development and Commercialization of Novel Oral Tablet KDS2010 in Ongoing Phase 2 CardioMetabolic and Neurodegenerative Diseases

GlobeNewswire

8 days ago

NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes Collaboration for Development and Commercialization of Novel Oral Tablet KDS2010 in Ongoing Phase 2 CardioMetabolic and Neurodegenerative Diseases

Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer’s Disease

GlobeNewswire

8 days ago

Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer’s Disease

Argus Research

8 days ago

Daily – Vickers Top Insider Picks for 12/10/2024

Argus Research

9 days ago

Daily – Vickers Top Insider Picks for 12/09/2024

Argus Research

12 days ago

Daily – Vickers Top Insider Picks for 12/06/2024

Argus Research

13 days ago

Daily – Vickers Top Insider Picks for 12/05/2024

Argus Research

14 days ago

Daily – Vickers Top Insider Picks for 12/04/2024

Argus Research

15 days ago

Daily – Vickers Top Insider Picks for 12/03/2024

Argus Research

16 days ago

Daily – Vickers Top Insider Picks for 12/02/2024

Argus Research

19 days ago

Daily – Vickers Top Insider Picks for 11/29/2024

Argus Research

21 days ago

Daily – Vickers Top Insider Picks for 11/27/2024

Argus Research

22 days ago

Daily – Vickers Top Insider Picks for 11/26/2024

Argus Research

23 days ago

Daily – Vickers Top Insider Picks for 11/25/2024

MT Newswires

a month ago

Scilex Gets Nasdaq's Noncompliance Notification

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/22/2024

Scilex Holding Company Announces Receipt of Notice from Nasdaq

GlobeNewswire

a month ago

Scilex Holding Company Announces Receipt of Notice from Nasdaq

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/21/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/20/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/19/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/18/2024

Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

GlobeNewswire

a month ago

Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/15/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/14/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/13/2024

GlobeNewswire

a month ago

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/11/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/08/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/07/2024

MT Newswires

a month ago

Scilex Shares Rise After Denali Capital's Registration Statement for Semnur Deal

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

GlobeNewswire

a month ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/06/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/05/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 11/04/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 11/01/2024

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 11/01/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 10/31/2024

Pleasing Signs As A Number Of Insiders Buy Scilex Holding Stock

Simply Wall St.

2 months ago

Pleasing Signs As A Number Of Insiders Buy Scilex Holding Stock

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 10/30/2024

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms

GlobeNewswire

2 months ago

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 10/29/2024

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

GlobeNewswire

2 months ago

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 10/28/2024

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

GlobeNewswire

2 months ago

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 10/25/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 10/24/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 10/23/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 10/22/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 10/21/2024

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 10/21/2024

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 10/18/2024

MT Newswires

2 months ago

Sector Update: Health Care Stocks Rise Premarket Wednesday

MT Newswires

2 months ago

Scilex Considers Spinning off Scilex Pharma Unit Among Other Options -- Shares Rise Pre-Bell

Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential

GlobeNewswire

2 months ago

Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

GlobeNewswire

2 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Zacks Small Cap Research

2 months ago

SCLX Grows Sales and Improves Finances

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024

GlobeNewswire

2 months ago

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024

MT Newswires

2 months ago

Scilex Holding Completes $50 Million Registered Convertible Financing

Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing

GlobeNewswire

2 months ago

Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing

MT Newswires

2 months ago

Scilex Holding Starts $50 Million Registered Direct Offering of Convertible Notes

GlobeNewswire

2 months ago

Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025

GlobeNewswire

3 months ago

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025

MT Newswires

3 months ago

Sector Update: Health Care Stocks Decline Monday Afternoon

MT Newswires

3 months ago

Scilex Holding to Pay $2 Million to Oramed Pharmaceuticals in Loan Accord

Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex’s Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan

GlobeNewswire

3 months ago

Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex’s Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan

Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®)

GlobeNewswire

3 months ago

Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®)

Private companies account for 46% of Scilex Holding Company's (NASDAQ:SCLX) ownership, while institutions account for 22%

Simply Wall St.

3 months ago

Private companies account for 46% of Scilex Holding Company's (NASDAQ:SCLX) ownership, while institutions account for 22%

Scilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference

GlobeNewswire

3 months ago

Scilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference

Scilex Holding Company Announces Acceptance of Presentation at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

GlobeNewswire

3 months ago

Scilex Holding Company Announces Acceptance of Presentation at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

Zacks Small Cap Research

3 months ago

SCLX Makes Move to Boost Shareholder Value

GlobeNewswire

3 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

GlobeNewswire

3 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024

GlobeNewswire

4 months ago

Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024

MT Newswires

4 months ago

Scilex Holding Says US FDA Approves Supplemental New Drug Application for Precision Dosing of Gloperba Label

Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label

GlobeNewswire

4 months ago

Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label

MT Newswires

4 months ago

Scilex Says New US Patent to Be Issued for Pain Treatment

Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain

GlobeNewswire

4 months ago

Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain

Zacks Small Cap Research

4 months ago

SCLX: Sales Accelerate

Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa

GlobeNewswire

4 months ago

Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024

GlobeNewswire

5 months ago

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

GlobeNewswire

5 months ago

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

GlobeNewswire

5 months ago

Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido® Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region

GlobeNewswire

5 months ago

Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido® Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region

MT Newswires

6 months ago

Scilex Holding Unit Semnur Pharmaceuticals, Denali Capital Acquisition Propose Merger

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

GlobeNewswire

6 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York

GlobeNewswire

6 months ago

Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024

GlobeNewswire

6 months ago

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024

Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.

GlobeNewswire

6 months ago

Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.

Share on Social Networks: